A new Centers for Disease Control and Prevention (CDC) study shows that 55 percent of Utah adults with heart disease also have arthritis, a painful condition that may be a barrier to physical activity—an essential strategy for people trying to manage and control their heart disease.
Ads by Google
Arthritis Pain Treatment
Arthritis may create an additional barrier to using physical activity to help people manage their heart disease, according to a study by the Centers for Disease Control and Prevention. Adults with both heart disease and arthritis are significantly more likely to be physically inactive than those with heart disease alone, the study said.
The study in the Morbidity and Mortality Weekly Report (MMWR), found that arthritis is common among those having heart disease. Approximately 57 percent of adults with heart disease have arthritis.
Arthritis affects more than half of adults with heart disease and appears to be a substantial barrier to utilizing physical activity to help manage their condition, according to a new Morbidity and Mortality Weekly Report (MMWR) study released today by the Centers for Disease Control and Prevention (CDC).
According to the Arthritis Foundation, the study underscores the importance of physical activity in effective management for adults with both arthritis and heart disease.
Rheumatoid arthritis (RA) is a chronic disease. It is mainly characterized by inflammation of the synovium (lining) of the joints. It can lead to long-term joint damage, chronic pain, loss of function and disability. Rheumatoid arthritis affects 1.3 million Americans.
Gout is a painful joint disease affecting about five million people in the United States. Gout is a form of arthritis that is caused by a build-up of uric acid in the blood.
On Friday, the Food and Drug Administration approved Uloric (febuxostat) giving gout sufferers a new drug to treat their disease. It is the first new treatment for gout in over 40 years. The drug is produced by Takeda Pharmaceuticals North America, Inc.
Uloric works by blocking the enzyme xanthine oxidase and therefore reducing levels of blood uric acid. It is a once-daily drug.
The American Academy of Orthopaedic Surgeons (AAOS) released its recommendations in December 2008 for "best" practice guidelines. In looking at the commonly used treatments for osteoarthritis (OA), they underscored that many lack support from scientific evidence.
The AAOS guideline targets treatment for patients with OA of the knee whose disease has not progressed to the point of needing joint replacement surgery. It offers 22 treatment recommendations. The guideline is aimed at primary care physicians as well as orthopedic surgeons.
A study that delivers the first clinical evidence that gene therapy can reduce the symptoms of patients with rheumatoid arthritis appeared in the February issue of Human Gene Therapy. The authors of the study, which was carried out in 1997 and 1998 under the direction of Dr. Peter Wehling, Düsseldorf, Germany, describe the findings of a study involving two patients with severe rheumatoid arthritis.
A new review finds no definitive connection between diet and rheumatoid arthritis (RA), a disease in which the body’s immune system attacks the lining of the joints.
As an individual’s rheumatoid arthritis progresses, his or her joints can become swollen and stiff, reducing mobility. While treatments are available to relieve some of these symptoms, no cure exists.
Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor β (FRβ), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA). During the last two decades, a second generation of folate antagonists has been designed to address some of the limitations of MTX, which include adverse side effects and resistance.
The American Academy of Orthopaedic Surgeons (AAOS) has approved and released an evidence-based clinical practice guideline on "Treatment of Osteoarthritis of the Knee". These guidelines were explicitly developed to include only treatments which are less invasive than knee replacement surgery. While a wide range of treatment options are available, they should always be tailored to individual patients after discussions with their physicians.
The Guidelines and Evidence Report recommends: